Adenoviral vectors for cancer gene therapy

Current Genomics

Volumn 3, Issue 3, 2002, Pages 163-180

  Relph, K L ^a   Pandha, H S ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; B7 ANTIGEN; CD40 LIGAND; CELL ADHESION MOLECULE; COMPLEMENTARY DNA; CYCLOPHOSPHAMIDE; CYTARABINE; CYTOCHROME P450; CYTOSINE DEAMINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROURACIL; GANCICLOVIR; GLYCOPROTEIN GP 100; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 12; MONOCLONAL ANTIBODY; NITROREDUCTASE; PHOSPHORIBOSYLTRANSFERASE; PROSTATE ANTIGEN; PROTEIN P16; PROTEIN P27; PROTEIN P53; RAS PROTEIN; RECOMBINANT GAMMA INTERFERON; THYMIDINE KINASE; TIOGUANINE; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR ALPHA; TUMOR VACCINE; UNINDEXED DRUG; VIRUS PROTEIN;

ANGIOGENESIS; BREAST CANCER; BYSTANDER EFFECT; CANCER CELL; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER THERAPY; COLORECTAL CANCER; CONTROLLED STUDY; CYTOTOXICITY; GENE DELETION; GENE EXPRESSION; GENE REPLACEMENT THERAPY; GENE THERAPY; HEAD AND NECK CANCER; HUMAN; IMMUNOMODULATION; INTERMETHOD COMPARISON; LUNG CANCER; MOUSE; NONHUMAN; OVARY CANCER; PROSTATE CANCER; REVIEW; SUICIDE GENE; TARGET CELL; TUMOR SUPPRESSOR GENE; VIRAL GENE DELIVERY SYSTEM; VIRUS RECOMBINANT; VIRUS REPLICATION;

ADENOVIRIDAE;

EID: 0036263282     PISSN: 13892029     EISSN: None     Source Type: Journal    
DOI: 10.2174/1389202023350516     Document Type: Review

References (142)

1. Gene therapy: The First Decade
2. Adenoviridae: The viruses and their replication
3. Adenoviruses
4. Adenoviral vectors
5. Role of a low-pH environment in adenovirus enhancement of the toxicity of a Pseudomonas exotoxin-epidermal growth factor conjugate
6. Development and application of adenoviral vectors for gene therapy of cancer
7. Feasibility of adenovirus-mediated gene transfer in vivo
8. An efficient and flexible system for construction of adenovirus vectors with insertions or deletions in early regions 1 and 3
9. Efficient manipulation of the human adenovirus genome as an infectious yeast artificial chromosome clone
10. Recombinational construction in Escherichia coli of infectious adenoviral genomes
11. Efficient generation of recombinant adenoviral vectors by Cre-lox recombination in vitro
12. Adenovirus technology for gene manipulation and functional studies
13. Ablation of E2A in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver
14. Characterization of an adenovirus gene transfer vector containing an E4 deletion
15. A helper-dependent adenovirus vector system: Removal of helper virus by Cre-mediated excision of the viral packaging signal
16. Persistence in muscle of an adenoviral vector that lacks all viral genes
17. Development and application of a minimal-adenoviral vector system for gene therapy of hemophilia A
18. High-capacity adenoviral vectors for gene transfer and somatic gene therapy
19. Reduced toxicity, attenuated immunogenicity and efficient mediation of human p53 gene expression in vivo by an adenovirus vector with deleted E1-E3 and inactivated E4 by GAL4-TATA promoter replacement
20. Cyclophosphamide diminishes inflammation and prolongs transgene expression following delivery of adenoviral vectors to mouse liver and lung
21. Transient immunosuppression with FK506 permits long-term expression of therapeutic genes introduced into the liver using recombinant adenoviruses in the rat
22. Gene therapy
23. Inhibition of tumor necrosis factor alpha decreases inflammation and prolongs adenovirus gene expression in lung and liver
24. Circumventing the immune response to adenovirus-mediated gene therapy
25. "Sero-switch" adenovirus-mediated in vivo gene transfer. circumvention of anti-adenovirus humoral immune defenses against repeat adenovirus vector administration by changing the adenovirus serotype
26. Canine adenovirus vectors. an alternative for adenovirus-mediated gene transfer
27. Transcomplementation of E1-deleted adenovirus. a new vector to reduce the possibility of codissemination of wild-type and recombinant adenoviruses
28. Safety testing programs for gene therapy viral vectors
29. New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication-competent adenoviruses
30. Early region 3 of adenovirus type 19 (subgroup D) encodes an HLA- binding protein distinct from that of subgroups B and C
31. Molecular characterization of replication-competent variants of adenovirus vectors and genome modifications to prevent their occurrence
32. Strategies to adapt adenoviral vectors for targeted delivery
33. Targeted gene delivery by tropism-modified adenoviral vectors
34. Evaluation of promoter strength for hepatic gene expression in vivo following adenovirus-mediated gene transfer
35. Adenovirus-mediated prodrug gene therapy for carcinoembryonic antigen- producing human gastric carcinoma cells in vitro
36. Osteocalcin-directed gene therapy for prostate-cancer bone metastasis
37. Melanoma-specific cytotoxicity induced by a tyrosinase promoter- enhancer/herpes simplex virus thymidine kinase adenovirus
38. Expression from cardiomyocyte-specific promoter after adenovirus-mediated gene transfer in vitro and in vivo
39. Construction and characterization of a recombinant adenovirus vector carrying the human preproinsulin gene under the control of the metallothionein gene promoter
40. Tumor localization of a radiolabeled bombesin analogue in mice bearing human ovarian tumors induced to express the gastrin-releasing peptide receptor by an adenoviral vector
41. Specific membrane receptor gene expression targeted with radiolabeled peptide employing the erbB-2 and DF3 promoter elements in adenoviral vectors
42. Latest developments in gene transfer technology. Achievements, perspectives, and controversies over therapeutic applications
43. P53 tumor suppressor gene therapy for cancer
44. Dendritic cells transduced with wild-type p53 gene elicit potent anti-tumour immune responses
45. Adenovirus-mediated transfer of p33ING1 with p53 drastically augments apoptosis in gliomas
46. The use of laser scanning cytometry to assess depth of penetration of adenovirus p53 gene therapy in human xenograft biopsies
47. Bivariate analysis of the p53 pathway to evaluate Ad-p53 gene therapy efficacy
48. Enhanced tumor suppressor gene therapy via replication-deficient adenovirus vectors expressing an N-terminal truncated retinoblastoma protein
49. Adenovirus-mediated retinoblastoma gene therapy suppresses spontaneous pituitary melanotroph tumors in Rb+/- mice
50. A recombinant adenovirus expressing p27Kip1 induces cell cycle arrest and loss of cyclin-Cdk activity in human breast cancer cells
51. Effects of a recombinant adenovirus expressing WAF1/Cip1 on cell growth, cell cycle, and apoptosis
52. Effects of adenovirus-mediated p16INK4A expression on cell cycle arrest are determined by endogenous p16 and Rb status in human cancer cells
53. The p21 cyclin-dependent kinase inhibitor suppresses tumorigenicity in vivo
54. In vivo gene therapy with p53 or p21 adenovirus for prostate cancer
55. Cell cycle arrest and inhibition of tumor cell proliferation by the p16INK4 gene mediated by an adenovirus vector
56. Inhibition of esophageal cancer proliferation by adenovirally mediated delivery of p16INK4
57. Induction of apoptosis and inhibition of tumorigenicity and tumor growth by adenovirus vector-mediated fragile histidine triad (FHIT) gene overexpression
58. Growth inhibition of prostate cancer by an adenovirus expressing a novel tumor suppressor gene, pHyde
59. Cancer gene therapy mediated by CTS1, a p53 derivative advantage over wild-type p53 in growth inhibition of human tumors overexpressing MDM2
60. Candidate tumor suppressor RIZ is frequently involved in colorectal carcinogenesis
61. Losses of the tumor suppressor BIN1 in breast carcinoma are frequent and reflect deficits in programmed cell death capacity
62. Adenovirus-mediated expression of PML suppresses growth and tumorigenicity of prostate cancer cells
63. A recombinant bcl-x s adenovirus selectively induces apoptosis in cancer cells but not in normal bone marrow cells
64. bcl-xs gene therapy induces apoptosis of human mammary tumors in nude mice
65. Adenovirus-mediated overexpression of the transcription factor E2F-1 induces apoptosis in human breast and ovarian carcinoma cell lines and does not require p53
66. Adenovirally transferred p16INK4/CDKN2 and p53 genes cooperate to induce apoptotic tumor cell death
67. The p53-independent tumoricidal activity of an adenoviral vector encoding a p27-p16 fusion tumor suppressor gene
68. Pancreatic carcinoma cell killing via adenoviral mediated delivery of the herpes simplex virus thymidine kinase gene
69. Applying the herpes simplex virus thymidine kinase/ganciclovir approach to ovarian cancer. An effective in vitro drug-sensitization system
70. The promise and reality of cancer gene therapy
71. Adenovirus-mediated suicide gene therapy for experimental bladder cancer
72. A phase I study of recombinant adenovirus vector-mediated intraperitoneal delivery of herpes simplex virus thymidine kinase (HSV-TK) gene and intravenous ganciclovir for previously treated ovarian and extraovarian cancer patients
73. Enzyme/prodrug gene therapy approach for breast cancer using a recombinant adenovirus expressing Escherichia coli cytosine deaminase
74. Suicide gene therapy
75. In vivo adenovirus-mediated gene transfer of the Escherichia coli cytosine deaminase gene to human colon carcinoma-derived tumors induces chemosensitivity to 5-fluorocytosine
76. Phase I study of direct administration of a replication deficient adenovirus vector containing the E. coli cytosine deaminase gene to association with the oral administration of the pro-drug 5-fluorocytosine
77. Gene therapy for tumors of the central nervous system
78. Molecular Biology of Cancer. Oncogenes
79. Growth inhibitory effect of anti-K-ras adenovirus on lung cancer cells
80. Neoplastic reversion accomplished by high efficiency adenoviral- mediated delivery of an anti-ras ribozyme
81. Anti-oncogene ribozymes for cancer gene therapy
82. An intracellular anti-erbB-2 single-chain antibody is specifically cytotoxic to human breast carcinoma cells overexpressing erbB-2
83. A phase I study of recombinant adenovirus vector-mediated delivery of an anti-erbB-2 single-chain (sFv) antibody gene for previously treated ovarian and extraovarian cancer patients
84. Adenovirus-mediated transduction of ribozymes abrogates HER-2/neu and pleiotrophin expression and inhibits tumor cell proliferation
85. Antisense epidermal growth factor receptor delivered by adenoviral vector blocks tumor growth in human gastric cancer
86. Effects of MYC oncogene antagonist, MAD, on proliferation, cell cycling, and the malignant phenotype of human brain tumor cells
87. Antitumor effects of an adenovirus expressing antisense insulin-like growth factor I receptor on human lung cancer cell lines
88. Essentials of Immunology
89. Intratumoral injection of an adenovirus expressing interleukin 2 induces regression and immunity in a murine breast cancer model
90. In vivo cancer gene therapy with a recombinant interleukin-2 adenovirus vector
91. Intratumoral coinjection of adenoviral vectors expressing IL-2 and IL- 12 results in enhanced frequency of regression of injected and untreated distal tumors
92. Direct intratumoral injection of a adenovirus expression interleukin- 12 induces regression and long-lasting immunity that is associated with highly localized expression of interleukin-12
93. Genetic immunotherapy of established tumors with adenovirus-murine granulocyte-macrophage colony-stimulating factor
94. Induction of antitumor immunity by direct intratumoral injection of a recombinant adenovirus vector expressing interleukin-12
95. Neuroblastoma regression and immunity induced by transgenic expression of interleukin-12
96. Tumour immunotherapy using an adenoviral vector expressing a membrane- bound mutant of murine TNF alpha
97. Autologous lymphocyte responses to adenovirus-B7-1-transduced human cancer cells
98. Therapeutic effectiveness of the immunity elicited by P815 tumor cells engineered to express the B7-2 costimulatory molecule
99. Interleukin 12 and B7-1 costimulatory molecule expressed by an adenovirus vector act synergistically to facilitate tumor regression
100. B7.1 and cytokines. Synergy in cancer gene therapy
101. B7-1 gene transfer into human cancer cells by infection with an adenovirus-B7 (Ad-B7) expression vector
102. Therapeutic antitumor response after immunization with a recombinant adenovirus encoding a model tumor-associated antigen
103. Immunogene therapy for murine melanoma using recombinant adenoviral vectors expressing melanoma-associated antigens
104. Naked DNA and adenoviral immunizations for immunotherapy of prostate cancer. A phase I/II clinical trial
105. A comparison of gene transfer methods in human dendritic cells
106. Genetic immunization for the melanoma antigen MART-1/Melan-A using recombinant adenovirus-transduced murine dendritic cells
107. Dendritic cells loaded with MART-1 peptide or infected with adenoviral construct are functionally equivalent in the induction of tumor- specific cytotoxic T lymphocyte response in patients with melanoma
108. Enhanced immune response to the melanoma antigen gp100 using recombinant adenovirus-transduced dendritic cells
109. Dendritic cell-based genetic immunization in mice with a recombinant adenovirus encoding murine TRP2 induces effective anti-melanoma immunity
110. Viral recombinant vaccines to the E6 and E7 antigens of HPV-16
111. Dendritic cells modified to express CD40 ligand elicit therapeutic immunity against preexisting murine tumors
112. Granulocyte-macrophage colony-stimulating factor gene transfer to dendritic cells or epidermal cells augments their antigen-presenting function including induction of anti-tumor immunity
113. Adenovirus-enhanced receptor-mediated transferrinfection for the generation of tumor vaccines
114. Gene therapy strategies for the treatment of pituitary tumours
115. Suppression of tumor angiogenesis and growth by gene transfer of a soluble form of vascular endothelial growth factor receptor into a remote organ
116. Antiangiogenic gene therapy of cancer utilizing a recombinant adenovirus to elevate systemic endostatin levels in mice
117. Viral vector-mediated transduction of a modified platelet factor 4 cDNA inhibits angiogenesis and tumor growth
118. Application of a tumor suppressor (C-CAM1)-expressing recombinant adenovirus in androgen-independent human prostate cancer therapy, a preclinical study
119. Schedule-dependence of C-CAM1 adenovirus gene therapy in a prostate cancer model
120. Development of recombinant adenoviruses that drive high level expression of the human metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 and -2 genes. Characterization of their infection smooth muscle cells and human MCF-7 adenocarcinoma cells
121. Combination therapy with suicide and cytokine genes for hepatic metastases of lung cancer
122. Combination gene transfer to potentiate tumor regression
123. A recombinant adenovirus expressing wild type p53 induces apoptosis in drug-resistant human breast cancer cells. A gene therapy approach for drug-resistant cancers
124. Sensitization of human breast cancer cells to cyclophosphamide and ifosfamide by transfer of a liver cytochrome P450 gene
125. Molecular chemotherapy combined with radiation therapy enhances killing of cholangiocarcinoma cells in vitro and in vivo
126. Spatial and temporal control of gene therapy using ionizing radiation
127. Gene therapy of cancer
128. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells
129. Prostate attenuated replication competent adenovirus (ARCA) CN706, a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells
130. Selectivity of a replication-competent adenovirus for human breast carcinoma cells expressing the MUC1 antigen
131. Prostate-specific antigen promoter/enhancer driven gene therapy for prostate cancer. Construction and testing of a tissue-specific adenovirus vector
132. Tumor-specific, replication-competent adenovirus vectors overexpressing the adenovirus death protein
133. Therapy of head and neck squamous cell carcinoma with an oncolytic adenovirus expressing HSV-tk
134. Effective gene therapy for pancreatic cancer by cytokines mediated by restricted replication-competent adenovirus
135. Complementary adenoviral vectors for oncolysis
136. Adeno-associated virus (AAV) Rep protein enhances the generation of a recombinant mini-adenovirus (Ad) utilizing an Ad/AAV hybrid virus
137. Site-specific integration of a transgene mediated by a hybrid adenovirus/adeno-associated virus vector using the Cre/loxP-expression- switching system
138. Integrating adenovirus-adeno-associated virus hybrid vectors devoid of all viral genes
139. Site-specific integration mediated by a hybrid adenovirus/adeno-associated virus vector
140. Adeno-retroviral chimeric viruses as in vivo transducing agents
141. Adenoviral/retroviral vector chimeras. A novel strategy to achieve high-efficiency stable transduction in vivo
142. An adenovirus-Epstein-Barr virus hybrid vector that stably transforms cultured cells with high efficiency